The securities litigation law firm of Brower Piven, A Professional
Corporation, announces that a class action lawsuit has been commenced in
the United States District Court for the District of New Jersey on
behalf of purchasers of Aerie Pharmaceuticals, Inc. (“Aerie” or the
“Company”) (Nasdaq: AERI) securities during the period between August 6,
2014 and April 23, 2015, inclusive (the “Class Period”). Investors who
wish to become proactively involved in the litigation have until June
29, 2015 to seek appointment as lead plaintiff.
If you have suffered a loss from investment in Aerie securities
purchased on or after August 6, 2014 and held through the revelation of
negative information during and/or at the end of the Class Period, as
described below, and would like to learn more about this lawsuit and
your ability to participate as a lead plaintiff, without cost or
obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html.
You may also request more information by contacting Brower Piven either
by email at hoffman@browerpiven.com
or by telephone at (410) 415-6616. No class has yet been certified in
the above action. Members of the Class will be represented by the lead
plaintiff and counsel chosen by the lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must
apply to be appointed lead plaintiff and be selected by the Court. The
lead plaintiff will direct the litigation and participate in important
decisions including whether to accept a settlement for the Class in the
action. The lead plaintiff will be selected from among applicants
claiming the largest loss from investment in Company securities during
the Class Period. Brower Piven also encourages anyone with
information regarding the Company’s conduct during the period in
question to contact the firm, including whistleblowers, former
employees, shareholders and others.
The complaint accuses the defendants of violations of the Securities
Exchange Act of 1934 by virtue of the defendants’ failure to disclose
during the Class Period adverse information regarding the Company’s
prospects for RhopressaTM, including that RhopressaTM
was not performing as well as timolol and would not lead to commercial
success for Aerie.
According to the complaint, following the Company’s April 23, 2015
announcement that the Phase 3 registration trial for RhopressaTM
did not meet its primary efficacy endpoint of demonstrating
non-inferiority of intraocular pressure (IOP) lowering for once-daily
RhopressaTM compared to twice-daily timolol, the most widely
used comparator in registration trials for glaucoma, the value of Aerie
shares declined significantly.
Attorneys at Brower Piven have extensive experience in litigating
securities and other class action cases and have been advocating for the
rights of shareholders since the 1980s. If you choose to retain counsel,
you may retain Brower Piven without financial obligation or cost to you,
or you may retain other counsel of your choice. You need take no action
at this time to be a member of the class.
Copyright Business Wire 2015